Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

Darazam, 2021
 
NCT04521400
RCThigh-dose IFN beta-1aIFN beta-1aCOVID 19 hospitalizedsome concern
83/85 inconclusive
    Li, 2021
     
    ChiCTR2000029638
    RCTrecombinant super-compound interferon rSIFN-coIFN alphaCOVID 19 hospitalizedsome concern
    48/48 conclusif
    • demonstrated 76 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
    • suggested 1.9-fold increase in clinical improvement (14-day) with a moderate degree of certainty due to some concern in risk of bias
    • suggested 3.3-fold increase in clinical improvement (28-day) with a moderate degree of certainty due to some concern in risk of bias
    • suggested 74 % increase in viral clearance (time to event analysis only) with a moderate degree of certainty due to some concern in risk of bias
    SOLIDARITY (interferon), 2020
     
    NCT04315948
    RCTIFN beta-1acontrolCOVID 19 hospitalizedsome concern
    2063/2064 inconclusive
    • inconclusive 16 % increase in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias
    Synairgen SG016, 2020
     
    NCT04385095
    RCTSNG001 inhaled interferon betaplaceboCOVID 19 hospitalizedsome concern
    50/51 suggested
    • suggested 1.3-fold increase in clinical improvement with a moderate degree of certainty due to some concern in risk of bias
    • suggested 2.2-fold increase in clinical improvement (28-day) with a moderate degree of certainty due to some concern in risk of bias

    COVID-19 mild to moderate meta-analysis

    Pandit, 2021
     
    CTRI/2020/06/026087
    RCTpeginterferonstandard of careCOVID-19 mild to moderatesome concern
    20/20 suggested
    • inconclusive 7.8-fold increase in clinical improvement (14-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
    • suggested 9.2-fold increase in viral clearance by day 14 with a moderate degree of certainty due to some concern in risk of bias
    Fu, 2020
     
    ChiCTR2000030262
    RCTinterferon / TFF2standard of careCOVID-19 mild to moderatesome concern
    40/40 conclusif
    • statistically significant demonstrated 1,000 % decrease in viral clearance (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
    Jagannathan, 2020
     
    NCT04331899
    RCTpeginterferonplaceboCOVID-19 mild to moderatesome concern
    60/60 inconclusive

      COVID-19 severe or critically meta-analysis

      Darazam (COVIFERON Interferon beta-1a), 2021
       
      NCT04343768
      RCTinterferonstandard of careCOVID-19 severe or criticallysome concern
      20/20 suggested
      • suggested 1.4-fold increase in clinical improvement,clinical improvement (time to event analysis only) with a moderate degree of certainty due to some concern in risk of bias
      Darazam (COVIFERON Interferon beta-1b), 2021
       
      NCT04343768
      RCTIFN beta-1bstandard of careCOVID-19 severe or criticallysome concern
      20/20 inconclusive
        Rahmani, 2020
         
        IRCT20100228003449N2
        RCTIFN beta-1bstandard of careCOVID-19 severe or criticallysome concern
        40/40 conclusif
        • demonstrated 2.4-fold increase in clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
        4 studies excluded by filtering options (2 RCT / 2 OBS)

        PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
        Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).